Report: U.S. hospitals experience more than 60 Ebola scares
NEW YORK — Hospitals and state laboratories in the United States have processed more than 60 Ebola scares over the course of the last few weeks, according to a report from ABC News.
Hospitals in 27 states notified the Centers for Disease Control and Prevention of the illnesses, doing so to be cautious due to the ongoing outbreak in Guinea, Liberia and Sierra Leone. Of the 68 cases reported, 58 were false alarms; blood samples of the remaining cases were sent out for testing.
The CDC is urging healthcare providers to ask patients about travel history to help with identifying potential cases, ABC News reported. The total number of deaths from the outbreak totals 1,229, and 2,240 people have been infected since March.
Pharmasmart completes initial testing phase for screening unit
ROCHESTER, N.Y. — PharmaSmart's PS2000 (D)estination completed its first alpha test inside a regional grocer, the company announced. Preliminary survey results received from the patients testing the unit inside the pharmacy reported that ease of use, ease of use, multi-biometric features, patented cuff size, virtual pharmacist and interoperability with pharmacy systems as the product's best features.
The company also said that the pharmacy staff overseeing the testing provided excellent anecdotal feedback regarding clinical features and benefit to healthcare objectives of their patients at point of care.
The company is targeting commercialization in late 2014 or early 2015. The PS2000 (D)estination will be showcased in booth #1727 at NACDS TSE.
FDA approves GSK’s Arnuity Ellipta
LONDON — GlaxoSmithKline announced FDA approval for Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid medicine for the treatment of asthma in patients 12 years of age and older.
"The approval of Arnuity Ellipta is an important development for GSK and our expanding respiratory portfolio. It is the first asthma treatment from our new portfolio to have gained approval in the US and enables us to begin expanding the range of medicines that we offer to physicians and appropriate patients," said Darrell Baker, SVP and head, GSK global respiratory franchise.
The approved dosage strengths are 100 mcg and 200 mcg. Arnuity is delivered by the dry powder inhaler Ellipta, which is also used across a range of respiratory medications in GSK's portfolio.